Aquestive Therapeutics, Inc. (NASDAQ:AQST) is set to announce second quarter earning results on Tuesday 4th August 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, AQST to report 2Q20 loss of $ 0.43 per share.
For the full year, analysts anticipate top line of $ 38.42 million, while looking forward to loss of $ 1.65 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 35.00 million ~ $ 45.00 million
Click Here For More Historical Outlooks Of Aquestive Therapeutics, Inc.
Previous Quarter Performance
Aquestive Therapeutics, Inc. announced loss for the first quarter of $ 0.49 per share, from the revenue of $ 8.77 million. The quarterly revenues fell 30.62 percent compared with the same quarter last year. Street analysts expected Aquestive Therapeutics, Inc. to report loss of $ 0.47 per share on revenue of $ 10.07 million for the first quarter. The bottom line results missed street analysts by $ 0.02 or 4.26 percent, at the same time, top line results fell short of analysts by $ 1.3 million or 12.91 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of Aquestive Therapeutics, Inc.
Stock Performance
According to the previous trading day, closing price of AQST was $ 5.69, representing a 303.55 % increase from the 52 week low of $ 1.41 and a 43.1 % decrease over the 52 week high of $ 10.00.
The company has a market capital of $ 191.09 million and is part of the Healthcare sector and Biotechnology industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”AQST” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Aquestive Therapeutics, Inc., a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery in the United States and internationally. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of recurrent epileptic seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of Amyotrophic Lateral Sclerosis.
